浙江佐力药业股份有限公司 2016 年第三季度报告全文 浙江佐力药业股份有限公司 2016 年第三季度报告 2016-061 2016 年 10 月 1 浙江佐力药业股份有限公司 2016 年第三季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人俞有强、主管会计工作负责人陈国芬及会计机构负责人(会计主 管人员)叶利声明：保证季度报告中财务报告的真实、完整。 2 浙江佐力药业股份有限公司 2016 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,998,676,816.28 | 1,850,546,582.90 | | 8.00% | | 归 ...

浙江佐力药业股份有限公司 2016 年半年度报告全文 浙江佐力药业股份有限公司 2016 年半年度报告 2016-046 2016 年 08 月 1 浙江佐力药业股份有限公司 2016 年半年度报告全文 第一节 重要提示、释义 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性、完整性承担个别及连带责任。 所有董事均已出席了审议本报告的董事会会议。 公司负责人俞有强、主管会计工作负责人陈国芬及会计机构负责人(会计主 管人员)叶利声明：保证年度报告中财务报告的真实、准确、完整。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 重要提示、释义 2 | | --- | | 第二节 公司基本情况简介 6 | | 第三节 董事会报告 10 | | 第四节 重要事项 29 | | 第五节 股份变动及股东情况 36 | | 第六节 董事、监事、高级管理人员情况 41 | | 第七节 财务报告 43 | | 第八节 备查文件目录 121 | 浙江佐力药业股份有限公司 2016 年半年度报告全文 释义 | 释义项 | ...

浙江佐力药业股份有限公司 2016 年第一季度报告全文 浙江佐力药业股份有限公司 2016 年第一季度报告 2016-023 2016 年 04 月 1 浙江佐力药业股份有限公司 2016 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 211,564,934.88 | 162,010,000.71 | 30.59% | | 归属于上市公司股东的净利润（元） | 23,189,153.52 | 22,621,477.40 | 2.51% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 21,594,846.04 | 20,341,550.26 | 6.16% | | 经营活动产生的现 ...

浙江佐力药业股份有限公司 2015 年年度报告全文 浙江佐力药业股份有限公司 2015 年年度报告 公告编号：2016-008 2016 年 04 月 1 浙江佐力药业股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 释义 | 释义项 | 指 | 释义内容 | | --- | --- | --- | | 佐力药业/公司/本公司 | 指 | 浙江佐力药业股份有限公司 | | 珠峰药业 | 指 | 青海珠峰冬虫夏草药业有限公司，公司控股子公司，公司持有珠峰药业 51%股权 | | 珠峰虫草公司 | 指 | 青海珠峰虫草药业集团有限公司，持有珠峰药业 49%股权 | | 珠峰原料公司 | 指 | 青海珠峰冬虫夏草原料有限公司 | | 凯欣医药 | 指 | 浙江凯欣医药有限公司，公司控股子公司，公司持有凯欣医药 65%股权 | | 凯润制药公司 | 指 | 浙江凯欣医药有限公司的自然人股东刘利辉及少数股东控制的企业 | | 乌灵合伙 | 指 | 德清县乌灵股权投资合伙企业（有限合伙），本次非公开发行对象之一，公司及 控股子公司部分董事、监事、高级管理人员、骨干员工及其他出资人参与出资设 | | | ...

浙江佐力药业股份有限公司 2015 年第三季度报告全文 浙江佐力药业股份有限公司 2015 年第三季度报告 2015-098 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人俞有强、主管会计工作负责人陈国芬及会计机构负责人(会计主管人员)叶利声明：保证季 度报告中财务报告的真实、完整。 2 浙江佐力药业股份有限公司 2015 年第三季度报告全文 第二节 公司基本情况 2015 年 10 月 1 浙江佐力药业股份有限公司 2015 年第三季度报告全文 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 1,876,691,386.18 | | 1,181,516,451.03 | ...

浙江佐力药业股份有限公司 2015 年半年度报告全文 浙江佐力药业股份有限公司 2015 年半年度报告 2015-075 2015 年 08 月 1 浙江佐力药业股份有限公司 2015 年半年度报告全文 第一节 重要提示、释义 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性、完整性承担个别及连带责任。 所有董事均已出席了审议本报告的董事会会议。 | 释义项 | 指 | 释义内容 | | --- | --- | --- | | 佐力药业/公司/本公司 | 指 | 浙江佐力药业股份有限公司 | | 珠峰药业 | 指 | 青海珠峰冬虫夏草药业有限公司，公司控股子公司，公司持有珠峰药业 51%股权 | | 珠峰虫草公司 | 指 | 青海珠峰虫草药业集团有限公司，持有珠峰药业 49%股权 | | 珠峰原料公司 | 指 | 青海珠峰冬虫夏草原料有限公司，青海珠峰虫草药业有限公司投资设立的另一子公司 | | 凯欣医药 | 指 | 浙江凯欣医药有限公司，公司控股子公司，公司持有凯欣医药 65%股权 | | 凯润制药公司 | 指 | 浙 ...

Financial Performance - Total revenue for Q1 2015 reached ¥162,010,000.71, representing a 54.72% increase compared to ¥104,713,850.08 in the same period last year[7] - Net profit attributable to shareholders was ¥22,621,477.40, up 20.42% from ¥18,784,919.86 year-on-year[7] - Basic earnings per share increased by 16.67% to ¥0.07 from ¥0.06 in the same period last year[7] - Operating revenue for the period was 162.01 million RMB, an increase of 54.72% year-on-year, attributed to the consolidation of two subsidiaries and growth in sales of the Wuling product series[19] - The company reported a total profit of CNY 27,305,134.38 for Q1 2015, compared to CNY 20,853,882.08 in the same quarter last year, marking a 30.5% increase[48] - The total comprehensive income for Q1 2015 was CNY 24,743,705.77, up from CNY 18,784,919.86 in Q1 2014[49] Cash Flow - Net cash flow from operating activities was -¥68,390,346.80, a decline of 338.99% compared to -¥15,578,894.00 in the previous year[7] - The net cash outflow from operating activities was 68.39 million RMB, an increase of 338.99% year-on-year, mainly due to reduced bill discounting and increased operational scale[21] - Cash inflow from sales of goods and services was CNY 56,698,856.34, down from CNY 74,932,523.47, reflecting a decline of approximately 24%[58] - Total cash outflow from operating activities was CNY 111,253,826.10, compared to CNY 98,446,979.49 in the previous period, an increase of about 13%[58] - The ending balance of cash and cash equivalents was CNY 143,026,792.84, down from CNY 292,232,214.13 in the previous period, a decrease of about 51%[57] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,174,081,228.90, a decrease of 0.63% from ¥1,181,516,451.03 at the end of the previous year[7] - Total liabilities decreased from CNY 309,753,667.24 to CNY 277,574,739.34, a reduction of about 10.4%[41] - Current assets totaled CNY 543,873,228.05, slightly down from CNY 547,903,938.01, indicating a decrease of about 0.5%[39] - Cash and cash equivalents decreased significantly from CNY 249,313,200.12 to CNY 143,026,792.84, a drop of approximately 42.6%[39] - Accounts receivable increased from CNY 111,232,423.14 to CNY 202,848,007.73, representing an increase of about 82.3%[39] Investments and Acquisitions - The company completed acquisitions of Zhu Feng Pharmaceutical and Kai Xin Pharmaceutical in 2014, expanding its product range and business operations[10] - The increase in revenue was primarily due to the acquisition of 51% of Zhu Feng Pharmaceutical and 67% of Kai Xin Pharmaceutical, which were included in the consolidated financial statements[23] - The company has committed to invest 15,000 million RMB in Everest Pharmaceutical, acquiring 31.94% equity and increasing its stake to 51%[32] - The investment in Kai Xin Pharmaceutical amounts to 2,400 million RMB, resulting in a 65% equity stake after the transaction[32] - The company is actively pursuing merger and acquisition opportunities in the pharmaceutical industry, with a major investment matter currently undergoing approval processes[25] Research and Development - Significant progress was made in R&D projects, including the large-scale clinical research of Wu Ling capsules, which is expected to support the market cultivation of Wu Ling series products[23] - The company is currently in the clinical trial phase for Ling Lian Hua granules, aiming to determine its efficacy and safety for large-scale clinical applications[23] - The company is enhancing its core competitiveness through in-depth research on Wu Ling powder and developing new products from medicinal fungi[23] - The company has initiated the development of new chemical drug formulations, with several products currently under review for production approval[23] Shareholder Information - The total number of shareholders at the end of the reporting period was 21,255[12] - Shareholder equity attributable to shareholders rose by 2.81% to ¥826,322,930.78 from ¥803,701,453.38 at the end of the previous year[7] - The cash dividend distribution plan for 2014 proposes a cash dividend of 2 RMB per 10 shares, totaling 6,336 million RMB, along with a capital reserve conversion of 22,176 million shares[34]

浙江佐力药业股份有限公司 2014 年年度报告全文 浙江佐力药业股份有限公司 2014 年年度报告 2015-016 2015 年 03 月 1 浙江佐力药业股份有限公司 2014 年年度报告全文 第一节 重要提示、目录和释义 公司负责人俞有强、主管会计工作负责人陈国芬及会计机构负责人(会计主 管人员)叶利声明：保证年度报告中财务报告的真实、准确、完整。 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司基本情况简介 6 | | 第三节 会计数据和财务指标摘要 8 | | 第四节 董事会报告 11 | | 第五节 重要事项 32 | | 第六节 股份变动及股东情况 42 | | 第七节 董事、监事、高级管理人员和员工情况 49 | | 第八节 公司治理 57 | | 第九节 财务报告 60 | | 第十节 备查文件目录 132 | 浙江佐力药业股份有限公司 2014 年年度报告全文 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料 不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确 性和完整性承担个别及连带责任。 所有董事均已出席了审议本报告的董事 ...

Financial Performance - Total operating revenue for the period was CNY 121,397,729.01, representing a 16.88% increase year-on-year[6] - Net profit attributable to shareholders increased by 22.70% to CNY 26,670,251.68 for the period[6] - Basic earnings per share rose by 22.74% to CNY 0.0842[6] - The company reported a net profit of 73.31 million yuan for the period, representing a 21.76% increase year-over-year[20] - Total revenue for the period reached 345.05 million yuan, reflecting a 12.29% growth compared to the same period last year[20] - Net profit for Q3 2014 reached CNY 27,687,451.82, representing a 27.5% increase from CNY 21,736,095.78 in Q3 2013[46] - Basic earnings per share for Q3 2014 were CNY 0.0842, compared to CNY 0.0686 in the same quarter last year, reflecting a growth of 22.5%[46] - Operating profit for the current period was ¥68,372,525.22, up from ¥54,879,617.44, reflecting a growth of approximately 24.48%[50] - Net profit for the current period was ¥74,326,971.47, compared to ¥60,208,940.40 in the previous period, indicating an increase of around 23.39%[51] Asset and Liability Changes - Total assets increased by 19.84% to CNY 1,128,755,523.13 compared to the end of the previous year[6] - The total liabilities increased to ¥289,428,466.39 from ¥169,379,973.17, marking a rise of approximately 70.8%[41] - Total assets as of Q3 2014 amounted to CNY 1,011,240,586.73, an increase from CNY 941,897,223.33 at the end of Q3 2013[45] - Total liabilities for Q3 2014 were CNY 238,535,516.42, up from CNY 169,379,973.17 in Q3 2013, indicating a rise of 40.9%[45] Cash Flow and Financial Management - The net cash flow from operating activities decreased by 73.69% to CNY -38,675,080.99[6] - Cash inflow from operating activities totaled ¥264,962,771.32, compared to ¥249,865,424.29 in the previous period, showing an increase of about 6.03%[56] - The net cash flow from operating activities was negative at -¥38,675,080.99, worsening from -¥22,266,527.31 in the previous period[56] - The total cash and cash equivalents at the end of the period decreased to 108,133,931.04 CNY from 303,114,600.81 CNY, showing a substantial reduction in liquidity[62] - The company incurred cash payments to employees totaling 53,861,089.85 CNY, an increase from 48,562,288.92 CNY in the previous period, reflecting higher labor costs[60] Shareholder Information - The total number of shareholders at the end of the reporting period was 24,854[11] - The largest shareholder, Yu Youqiang, holds 30.94% of the shares, with 73,507,500 shares pledged[11] - The total number of shares held by the top 10 unrestricted shareholders amounts to 92,679,508 shares, with the largest shareholder, Yu Youqiang, holding 24,502,500 shares[13] - The company has not engaged in any repurchase agreements during the reporting period[14] Strategic Acquisitions and Investments - The company acquired 51% of Qinghai Zhu Feng Winter Worm Summer Grass Pharmaceutical Co., Ltd. and 65% of Kaixin Pharmaceutical, indicating a strategic expansion[9] - The company completed the acquisition of Zhu Feng Pharmaceutical and Kai Xin Pharmaceutical, enhancing its product portfolio and market adaptability[20] - The company plans to invest CNY 15 million in Qinghai Zhu Feng Winter Worm Summer Grass Pharmaceutical Co., acquiring 31.94% equity and increasing its stake to 51%[31] - The company has allocated CNY 2.4 million to Zhejiang Kaixin Pharmaceutical Co., acquiring 47.5% equity and increasing its stake to 65%[32] Operational Developments - The company is advancing the GMP certification for its new lyophilized powder injection workshop to ensure compliance[20] - The company is actively promoting new products such as Ling Lianhua Granules and strengthening the integration of its business operations[20] - The company is conducting in-depth research on Wu Ling mushroom powder and has initiated Phase IV clinical trials for Ling Lian Hua granules[23] - The company has established a research center for medicinal fungi, with a total investment of CNY 3 million, achieving 86.88% of the planned progress[31] Corporate Governance and Commitments - The company has committed to not engage in any competitive activities that may harm the interests of Zhejiang Zhaoli Pharmaceutical Co., Ltd. and its shareholders[28] - The company guarantees equal exercise of shareholder rights and obligations, ensuring no undue benefits are sought from its major shareholder status[28] - The company has made commitments to avoid any competition with its subsidiaries, ensuring compliance with corporate governance[28] - The company emphasizes the importance of maintaining a stable management team to support its development[28]

Financial Performance - Total operating revenue for the first half of 2014 was RMB 223,647,552.70, representing a 9.95% increase compared to RMB 203,407,474.89 in the same period last year[17] - Net profit attributable to ordinary shareholders was RMB 47,404,519.65, up 23.22% from RMB 38,472,844.62 year-on-year[17] - The net cash flow from operating activities improved to RMB -8,956,100.82, a 37.08% reduction in losses compared to RMB -14,234,236.20 in the previous year[17] - Basic earnings per share increased to RMB 0.1496, reflecting a growth of 23.23% from RMB 0.1214 in the same period last year[17] - The total profit reached CNY 53.18 million, reflecting a growth of 23.58% compared to the same period last year[28] - Net profit attributable to shareholders was CNY 47.40 million, up 23.22% year-on-year[28] - The company reported a decrease in total equity attributable to ordinary shareholders to RMB 747,921,769.81, down 3.18% from RMB 772,517,250.16 at the end of the previous year[17] Strategic Initiatives - The company plans to acquire 51% of Qinghai Zhu Feng Dong Chong Xia Cao Pharmaceutical Co., which produces medicinal fungi products, indicating a strategic move for business expansion[23] - The company is actively pursuing mergers and acquisitions, with significant progress in acquiring Qinghai Zhuofeng Cordyceps Pharmaceutical Co., Ltd.[26] - The company plans to invest 150 million CNY in Qinghai Zhuofeng Cordyceps Pharmaceutical Co., Ltd. to optimize product structure and enhance future growth[40] - The company aims to develop Wuling Capsules into a major modern Chinese medicine, with new production projects increasing capacity to 200 tons of Wuling mycelium powder and 450 million capsules annually[38] Research and Development - Research and development investment amounted to CNY 6.97 million, a rise of 6.75% compared to the previous year[28] - The company is in the process of developing new products, including new drug formulations and expanding its product structure[36] - The company has completed the construction of a national-level laboratory for medicinal fungi, enhancing its research capabilities[39] Market Position and Growth - The pharmaceutical industry in China is experiencing rapid growth due to population increase and aging, leading to a peak in drug production and sales[37] - The company has entered the basic drug supplement directory in Guangdong and Xinjiang, enhancing market presence[39] - The sales revenue of the main product, the Wuling series, was CNY 220.97 million, increasing by 12.26% from the previous year[30] Financial Management and Investments - The total amount of raised funds is RMB 42,581.76 million, with RMB 708.22 million invested during the reporting period and a cumulative investment of RMB 20,711.55 million[44] - The company has allocated RMB 16,111.55 million of the raised funds to project investments and RMB 4,600 million to permanently supplement working capital[44] - The commitment investment projects include a new production technology upgrade project with a total investment of RMB 9,238 million, achieving 99.06% of the planned progress[46] - The new annual production capacity project for 450 million capsules has a total investment of RMB 2,991 million, with a progress of 106.14%[46] Profit Distribution and Shareholder Relations - The company will not distribute cash dividends or issue bonus shares for this reporting period[6] - The company has implemented a profit distribution plan, distributing 5 CNY per 10 shares and increasing capital reserves by 12 shares per 10 shares[40] - The profit distribution plan for 2013 was approved by the board, supervisory board, and shareholders' meeting, ensuring compliance with company regulations[53] - Independent directors confirmed that the profit distribution plan aligns with the company's growth and protects the interests of all shareholders, especially minority shareholders[53] Risks and Compliance - The company is facing risks from industry policy changes, which may impact drug production and competition, and is actively monitoring these changes[42] - The acquisition of a 51% stake in Qinghai Zhuofeng may present integration risks, which the company is preparing to address[42] - The company has revised its profit distribution policies in accordance with the requirements of the China Securities Regulatory Commission and relevant regulatory bodies[52] Share Capital and Ownership - The total number of shares increased from 144,000,000 to 316,800,000 after the capital reserve conversion, representing a 120% increase[66] - The basic earnings per share decreased from 0.2672 to 0.1214 after the share increase, reflecting a 54.6% decline[67] - The company’s major shareholder, Zhejiang Kang En Bei, has pledged to avoid any actions that could harm the interests of Zhaoli Pharmaceutical and its shareholders[59] - The company emphasizes strict adherence to its articles of association and equal treatment of all shareholders[59] Financial Reporting and Compliance - The financial report for the first half of 2014 was not audited, which may affect the reliability of the financial data presented[81] - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect a true and complete picture of its financial status[102] - The company’s financial reports are prepared based on the principle of going concern, following actual transactions and events[102] Inventory and Asset Management - The inventory balance at the end of the period is 48,376,841.37 RMB, with a decrease in the provision for inventory depreciation to 171,853.19 RMB[182] - The fixed assets' net book value at the end of the period is 364,880,232.79 RMB, with a depreciation expense of 9,326,127.21 RMB for the current period[186] - The company reported a decrease in the provision for inventory depreciation due to the reversal of previous write-downs[185] Taxation and Government Grants - The corporate income tax rate applicable to the company is 25%, with a reduced rate of 15% for the years 2011 to 2013 due to high-tech enterprise status[150] - The company recognizes government grants as deferred income, which are allocated over the useful life of the related assets[145] - The company has received a government subsidy of 2,050,416.67 RMB related to tax incentives for hiring disabled individuals[177]